Novavax reported $17.53M in Net Income for its fiscal quarter ending in December of 2025.





Net Income Change Date
Adma Biologics USD 49.38M 12.95M Dec/2025
Agenus USD -10.63M 74.49M Dec/2025
AstraZeneca USD 3.08B 754M Mar/2026
BioCryst Pharmaceuticals USD 245.84M 232.95M Dec/2025
Cassava Sciences USD -12.54M 1.73M Dec/2025
Geron USD -31.14M 12.72M Dec/2025
GlaxoSmithKline GBP 1.74B 1.1B Mar/2026
MannKind USD -15.95M 23.93M Dec/2025
Merck USD -4.24B 7.2B Mar/2026
Minerva Neurosciences USD 1.44M 21.07M Dec/2024
Moderna USD -1.34B 517M Mar/2026
Novartis USD 2.41B 1.52B Dec/2025
Novavax USD 17.53M 219.91M Dec/2025
Pfizer USD -1.65B 5.19B Dec/2025
Sanofi EUR 1.61B 2.42B Mar/2026
Sarepta Therapeutics USD -412.23M 232.28M Dec/2025
TG Therapeutics USD 23.04M 367.86M Dec/2025